InvestorsHub Logo

TradingPro

04/15/21 9:31 AM

#355721 RE: farrell90 #355717

Merck probably calling their buds in congress, because they paid to play WTF... lol!

duchamp

04/15/21 9:36 AM

#355726 RE: farrell90 #355717

The FDA has just gone up a few notches in my book.


duchamp

Hungry_Ghost

04/15/21 9:38 AM

#355727 RE: farrell90 #355717

Merck pays 425 million for a DUD. Leo pays 5 million for a multi purpose platform wonder drug with a SI *426*. Nothing else needs to be said.

BRILACIDIN SI *426*

farrell90

04/15/21 1:52 PM

#355792 RE: farrell90 #355717

Ridgeback and Merck halt molnupiravir trial for Covid 19 hospitalized patients.

In addition to announcing the withdrawal of its vaccine and CD24Fc, Merck has also announced Ridgeback and Merck are halting Covid 19 trials for hospitalized patients with oral molnupiravir.

"Early study results on hospitalized patients found that the treatment is unlikely to reduce hospitalization stays and deaths, the companies said Thursday.

Merck said testing found that the drug, called molnupiravir, inhibits replication of the virus. But the trial of people who weren’t hospitalized was too small to show that the drug reduced clinical symptoms during their early treatment, Merck said.

Another surprise Merck announcement today reverses previous optimistic reports of molnupiravirs results for Covid19.

Brilacidin's competitors are dropping like flies.

Farrell

https://www.wsj.com/articles/merck-partner-halt-covid-19-treatment-trial-for-hospitalized-patients-11618483561